A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
Decitabine has been reported to have a clinically significant, often long lasting effect on
the platelet count in myelodysplastic syndromes(MDS). It is also reported that decitabine
could increase platelet counts by enhancing megakaryocyte maturation and platelet release.
Immune thrombocytopenia(ITP) is known as an immune-mediated acquired disease characterized by
transient or persistent decrease of the platelet count. However, refractory ITP is lacking of
effective treatments and the efficacy of decitabine in ITP remains poorly understood. Data
from this study may provide some idea of decitabine in the treatment of ITP.